



Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Effective on 12/08/2004.</b> Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). <b>FEE TRANSMITTAL</b> <b>For FY 2008</b>		<b>Complete if Known</b>		
		Application Number	10/760,091	
		Filing Date	January 16, 2004	
		First Named Inventor	Thomas L. CANTOR	
		Examiner Name	C. Cheu	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	Art Unit	1641		
TOTAL AMOUNT OF PAYMENT	(\$)	180.00	Attorney Docket No.	532212000624

<b>METHOD OF PAYMENT</b> (check all that apply)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify): _____	
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: 03-1952
Deposit Account Name: Morrison & Foerster LLP	
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, <b>except for the filing fee</b>
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

<b>FEE CALCULATION</b>							
<b>1. BASIC FILING, SEARCH, AND EXAMINATION FEES</b>							
	<b>FILING FEES</b>		<b>SEARCH FEES</b>		<b>EXAMINATION FEES</b>		
		<b>Small Entity</b>		<b>Small Entity</b>		<b>Small Entity</b>	
<b>Application Type</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fees Paid (\$)</b>
Utility	310	155	510	255	210	105	_____
Design	210	105	100	50	130	65	_____
Plant	210	105	310	155	160	80	_____
Reissue	310	155	510	255	620	310	_____
Provisional	210	105	0	0	0	0	_____
<b>2. EXCESS CLAIM FEES</b>							
						<b>Small Entity</b>	
<b>Fee Description</b>						<b>Fee (\$)</b>	<b>Fee (\$)</b>
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						210	105
Multiple dependent claims						370	185
<b>Total Claims</b>		<b>Extra Claims</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>	<b>Multiple Dependent Claims</b>		
_____ - 20 = _____		x _____	= _____		<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>	
HP = highest number of total claims paid for, if greater than 20.							
<b>Indep. Claims</b>		<b>Extra Claims</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>			
_____ - 3 = _____		x _____	= _____				
HP = highest number of independent claims paid for, if greater than 3.							
<b>3. APPLICATION SIZE FEE</b>							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$260 (\$130 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
<b>Total Sheets</b>	<b>Extra Sheets</b>	<b>Number of each additional 50 or fraction thereof</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>			
_____ - 100 = _____	/50 = _____	(round up to a whole number) x _____	= _____				
<b>4. OTHER FEE(S)</b>							
						<b>Fees Paid (\$)</b>	
Non-English Specification, \$130 fee (no small entity discount)							
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement						180.00	

<b>SUBMITTED BY</b>			
Signature		Registration No. (Attorney/Agent)	43,543
Name (Print/Type)	Peng Chen	Telephone	(858) 720-5117
		Date	December 14, 2007

I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill Nos. Box #1 – EM 057522185 US, Box #2 – EM 057522199 US, Box #3 – EM 057522208 US, Box #4 – EM 057522211 US, on the date shown below in four boxes addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Dated: December 14, 2007

Signature: Anthony Matson

(Anthony Matson)

Patent

Docket No. 532212000624



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Thomas L. CANTOR et al.

Serial No.: 10/760,091

Filing Date: January 16, 2004

For: METHODS FOR DIFFERENTIATING  
AND MONITORING PARATHYROID  
AND BONE STATUS RELATED  
DISEASES

Examiner: C. Cheu

Group Art Unit: 1641

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER MPEP § 724.02

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to the duty of disclosure in 37 C.F.R. § 1.56, Applicants hereby submit under MPEP § 724.02 the documents listed on the attached Form PTO/SB/08a/b. The attention of the Patent and Trademark Office is hereby directed to these documents because they are **SUBJECT TO PROTECTIVE ORDER** or **PROPRIETARY** information. It is respectfully requested that the Examiner consider the information during the prosecution of this application.

The document numbers 1-84 listed on the attached Form PTO/SB/08a/b are **SUBJECT TO PROTECTIVE ORDER** and should only be viewed by the Examiner or other authorized Patent and Trademark Office Employees. Pursuant to MPEP § 724.02, a copy of each document that is **SUBJECT TO PROTECTIVE ORDER** listed on the attached Form PTO/SB/08a/b is

enclosed in a sealed, clearly labeled envelope. Document numbers 1-75 are from *Nichols Institute Diagnostics, Inc. v. Scantibodies Clinical Laboratory, Inc. and Scantibodies Laboratory, Inc.*, U.S.D.C. for the Southern District of California, case number 02 CV 0046 B (JMA), appealed at the United States Court of Appeals for the Federal Circuit as case numbers 06-1087 and 06-1443. Document numbers 76-84 are from *Scantibodies Laboratory, Inc. v. Immutopics, Inc.*, U.S.D.C. for the Central District of California, Case No. CV04-08871 MRP (MANx). Scantibodies Laboratory, Inc. is the assignee of the present application.

Document number 85 listed on the attached Form PTO/SB/08a/b is **PROPRIETARY** and should only be viewed by the Examiner or other authorized Patent and Trademark Office Employees. Pursuant to MPEP § 724.02, a copy of the **PROPRIETARY** document listed on the attached Form PTO/SB/08a/b is enclosed in a sealed, clearly labeled envelope.

Pursuant to MPEP § 2004.13, Applicants point out the following:

- Exhibit M of document No. 3, "Claim Chart for U.S. Patent No. 6,030,790" submitted by Nichols, in which United States Patent number 6,689,566 (the '566 patent) is discussed. The present application is a Continuation of United States Patent number 6,743,590, which is a Continuation-in-Part of the '566 patent.
- Rebuttal Expert Report of Joseph O. Falkinham, III, Ph.D. (Document No. 13 in the present Form PTO/SB/08a/b), in which prosecution of the '566 patent is discussed.
- April 7, 2005 Declaration of Thomas L. Cantor (with the attached Exhibit A, Facsimile from Dr. Gao to Dr. Kao on September 21, 1998 and the attached Invoice Form) (Document No. 85 in the present Form PTO/SB/08a/b) in connection with U.S. Patent Application No. 10/617,489. In the declaration, a shipment of three PTH (1-84) Specific IRMA Kits on September 21, 1998 from Dr. Ping Gao, a named inventor of the '566 patent, to Dr. Pai C. Kao of the Mayo Clinic is disclosed.

- Deposition of Thomas Cantor, taken on August 27, 2003 (Document No. 51 in the present Form PTO/SB/08a/b) in which Mr. Cantor answered questions about the use of PTH (1-9) peptide (*See e.g.*, Document No. 51 at pages 78-80.)
- Confidential Deposition of Tom Cantor, taken on July 11, 2005 (Document No. 76 in the present Form PTO/SB/08a/b) may contain information potentially relevant to the Declaration of Thomas L. Cantor (Document No. 85 in the present Form PTO/SB/08a/b).
- At page 00245, lines 12-13 of the Confidential Deposition of Tom Cantor, taken on July 11, 2005 (Document No. 76 in the present Form PTO/SB/08a/b), the sales figure of "Immutopics BioActive PTH ELISA assays" is redacted.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_ is enclosed.
  - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.

- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_\_ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532212000624.

Dated: December 14, 2007

Respectfully submitted,

By   
Peng Chen  
Registration No.: 43,543  
MORRISON & FOERSTER LLP  
12531 High Bluff Drive, Suite 100  
San Diego, California 92130-2040  
(858) 720-5117